Bildkälla: Stockfoto

Cantargia Q2’22: Low Downside Risk at Present Valuation - Redeye

The two main events during and after the second quarter were the positive results from ASCO 2022 and the rights issue. We also discuss Canakinumab's failure in lung cancer and the share's record low market valuation.

The two main events during and after the second quarter were the positive results from ASCO 2022 and the rights issue. We also discuss Canakinumab's failure in lung cancer and the share's record low market valuation.
Börsvärldens nyhetsbrev
ANNONSER